Eli Lilly and Company (LLY)
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Eli Lilly and Company LLY will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025.
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Eli Lilly And Co LLY will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $4.94 in EPS and $13.66 billion in revenues as the company reports before market hours.
Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.
What Thursday's Earnings Mean for This Pharma Giant
Tomorrow, Eli Lilly (LLY), the world's largest drug company, reports earnings before the market opens. The options market is already predicting some major moves.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.
Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
3 Magnificent Stocks to Buy and Hold Forever
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
